Diagnosis of gastrointestinal stromal tumors: A consensus approach

摘要: As a result of major recent advances in understanding the biology gastrointestinal stromal tumors (GISTs), specifically recognition central role activating KIT mutations and associated protein expression these lesions, development novel effective therapy for GISTs using receptor tyrosine kinase inhibitor STI-571, have become focus considerable attention by pathologists, clinicians, patients. Stromal/mesenchymal tract long been source confusion controversy with regard to classification, line(s) differentiation, prognostication. Characterization pathway its phenotypic implications has helped resolve some but not all issues. Given now critical accurate reproducible pathologic diagnosis ensuring appropriate treatment patients GIST, National Institutes Health convened GIST workshop April 2001 goal developing consensus approach morphologic Key elements consensus, as described herein, are defining immunopositivity proposed scheme estimating metastatic risk based on tumor size mitotic count, recognizing that it is probably unwise use definitive term "benign" any at least present time.